T1	Participants 268 280	236 patients
T2	Participants 576 586	71 patient
T3	Participants 797 829	survival of PAN and CSS patients
T4	Participants 925 953	patients without HBV markers
T5	Participants 972 997	patients with HBV markers
T6	Participants 1002 1033	78 patients without HBV markers
T7	Participants 1124 1160	33 patients with PAN related to HBV,
